{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:34:56Z","timestamp":1791506096798,"version":"4.3.4"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sacubitril\/valsartan (SV) has been demonstrated to reduce cardiovascular mortality, hospitalization for heart failure and to induce reverse ventricular remodeling. The present study was designed to confirm the effects of SV in a selected population of patients with HFrEF and to evaluate the different responses between patients with an ischemic or a non-ischemic etiology. A total of 79 patients with indication of SV were recruited prospectively during a timelapse of 4 years. SV was overall associated to a reduction of end-diastolic and end-systolic volume, of NT-proBNP levels, furosemide dosage and NYHA functional class, together with an increase in EF. These changes were more evident in patients with non-ischemic dilated cardiomyopathy, who showed a significant improvement in ventricular volumes, ejection fraction, TAPSE and blood levels of NT-proBNP. Kaplan\u2013Meier curves confirmed a greater benefit in terms of ejection-fraction improvement in non-ischemic patients compared to the ischemic group. The results of the present study confirm the positive effect of SV on NYHA functional class, NT- proBNP, left ventricular volumes and EF in HFrEF patients, showing evidence of association of SV with ventricular remodeling in patients with dilated cardiomyopathy of non-ischemic etiology compared to the ischemic group.<\/jats:p>","DOI":"10.3390\/jcm12020621","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T02:29:57Z","timestamp":1673576997000},"page":"621","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril\/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology"],"prefix":"10.3390","volume":"12","author":[{"given":"Roberto","family":"Cemin","sequence":"first","affiliation":[{"name":"Division of Cardiology, San Maurizio Regional Hospital, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Casablanca","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Maurizio Regional Hospital, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-3322","authenticated-orcid":false,"given":"Luisa","family":"Foco","sequence":"additional","affiliation":[{"name":"Eurac Research, Institute for Biomedicine, University of L\u00fcbeck, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schoepf","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Maurizio Regional Hospital, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-3171","authenticated-orcid":false,"given":"Andrea","family":"Erlicher","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Maurizio Regional Hospital, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1569-0071","authenticated-orcid":false,"given":"Renato","family":"Di Gaetano","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Maurizio Regional Hospital, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9390-410X","authenticated-orcid":false,"given":"Davide","family":"Ermacora","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Maurizio Regional Hospital, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of Heart Failure: A Contemporary Perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199108013250508","article-title":"ACE Inhibitors\u2014A cornerstone of the treatment of heart failure","volume":"325","author":"Braunwald","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ehjcvp\/pvu006","article-title":"Pharmacotherapy in heart failure with reduced ejection fraction during the last 20 years, and the way ahead for precision medicine","volume":"1","author":"Zannad","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"105573","DOI":"10.1016\/j.phrs.2021.105573","article-title":"Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials","volume":"169","author":"Bao","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure. PARADIGM-HF Investigators and Committees","volume":"371","author":"Mcmurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Castrichini, M., Manca, P., Nuzzi, V., Barbati, G., De Luca, A., Korcova, R., Stolfo, D., Di Lenarda, A., Merlo, M., and Sinagra, G. (2020). Sacubitril\/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040906"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jchf.2020.05.010","article-title":"The PARAGON-HF Trial: Toward Extension to Patients with HF Middle Range Ejection Fraction","volume":"8","author":"Gronda","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e004962","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline Characteristics of Patients with Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ. Hearth Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared with Men with Heart Failure and Preserved Ejection Fraction","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1161\/CIRCULATIONAHA.120.047275","article-title":"Response by Jackson et al. to Letter Regarding Article, \u2018Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared with Men with Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF\u2019","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of Change in N-Terminal Pro\u2013B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment with Cardiac Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e006946","DOI":"10.1161\/CIRCHEARTFAILURE.119.006946","article-title":"Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril\/Valsartan","volume":"13","author":"Januzzi","year":"2020","journal-title":"Circ. Hearth Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","article-title":"Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF","volume":"7","author":"Balmforth","year":"2019","journal-title":"JACC. Heart Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10557-020-07036-3","article-title":"Comparison of the Effect of Sacubitril\/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy","volume":"34","author":"Ioannou","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ehjcvp\/pvaa125","article-title":"Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril\/valsartan treatment","volume":"8","author":"Lee","year":"2020","journal-title":"Eur. Hearth J. Cardiovasc. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Abumayyaleh, M., Pilsinger, C., El-Battrawy, I., Kummer, M., Kuschyk, J., Borggrefe, M., M\u00fcgge, A., Aweimer, A., and Akin, I. (2021). Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214989"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"(2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.21037\/cdt.2017.03.12","article-title":"Assessing observer variability: A user\u2019s guide","volume":"7","author":"Thomas","year":"2017","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.jacc.2019.03.510","article-title":"Sacubitril\/Valsartan, Cardiac Fibrosis, and Remodeling in Heart Failure","volume":"73","author":"Aimo","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Giallauria, F., Vitale, G., Pacileo, M., Di Lorenzo, A., Oliviero, A., Passaro, F., Calce, R., Parlato, A., Testa, C., and D\u2019Ambrosio, G. (2020). Sacubitril\/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061897"},{"key":"ref_24","first-page":"e79","article-title":"Response to Letters Regarding Article, \u201cMyocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy: A Contrast-Enhanced Cardiovascular Magnetic Study\u201d","volume":"6","author":"Masci","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/ejhf.1734","article-title":"Predictors of left ventricular remodelling in patients with dilated cardiomyopathy\u2014A cardiovascular magnetic resonance study","volume":"22","author":"Tayal","year":"2020","journal-title":"Eur. J. Hearth Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ahj.2011.10.001","article-title":"Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: Findings from IMPROVE HF","volume":"163","author":"Wilcox","year":"2012","journal-title":"Am. Hearth J."},{"key":"ref_27","first-page":"125","article-title":"Sacubitril\/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction","volume":"36","author":"Liu","year":"2020","journal-title":"Acta Cardiol. Sin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.639","article-title":"Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction","volume":"18","author":"Dini","year":"2016","journal-title":"Eur. J. Hearth Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0002-9149(99)00877-2","article-title":"Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy","volume":"85","author":"Ghio","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejheart.2007.03.001","article-title":"Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure","volume":"9","author":"Kjaergaard","year":"2007","journal-title":"Eur. J. Hearth Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.ijcha.2020.100486","article-title":"Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry","volume":"27","author":"Correale","year":"2020","journal-title":"IJC Hearth Vasc."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/2\/621\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:04:22Z","timestamp":1760119462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/2\/621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12020621"],"URL":"https:\/\/doi.org\/10.3390\/jcm12020621","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}